GR 64349 peptide acts as an agonist of neurokinin (NK2) receptor, which reduces NK2 response to kainate and AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), but not to NMDA (N-methyl-D-aspartate)
CAT No: R0803
CAS No: 137593-52-3
Synonyms/Alias: GR 64349;137593-52-3;136548-07-7;(3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(3R)-1-[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-2-oxopyrrolidin-3-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid;3-Lys-8-gly-R-lactam-9-leu-neurokinin A (3-10);Neurokinin A (3-10), lys(3)-gly(8)-R-lactam-leu(9)-;Neurokinin A (3-10), lysyl(3)-glycyl(8)-R-lactam-leucine(9)-;(3R-(1(S*(S*)),3R*))-L-Lysyl-L-alpha-aspartyl-L-seryl-L-phenylalanyl-N-(1-(1-(((1-(aminocarbonyl)-3-(methylthio)propyl)amino)carbonyl)-3-methylbutyl)-2-oxo-3-pyrrolidinyl)-L-valinamide;L-Valinamide, L-lysyl-L-alpha-aspartyl-L-seryl-L-phenylalanyl-N-(1-(1-(((1-(aminocarbonyl)-3-(methylthio)propyl)amino)carbonyl)-3-methylbutyl)-2-oxo-3-pyrrolidinyl)-, (3R-(1(S*(S*)),3R*))-;DA-63889;MS-31721;G12420;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C42H68N10O11S |
M.W/Mr. | 921.1 |
Sequence | KDSFVGLM(Modifications: Leu-7 = R-γ-lactam-Leu, Met-8 = C-terminal amide) |
Labeling Target | NK-2 tachykinin receptor |
Application | GR 64349 is a potent and selective agonist at the NK-2 tachykinin receptor, which Initiates changes in the colon, intestine and spinal cord. |
Appearance | White lyophilised solid |
Purity | >98% (or refer to the Certificate of Analysis) |
Activity | Agonist |
InChI | InChI=1S/C42H68N10O11S/c1-23(2)19-32(40(61)46-27(35(45)56)15-18-64-5)52-17-14-28(42(52)63)47-41(62)34(24(3)4)51-38(59)29(20-25-11-7-6-8-12-25)49-39(60)31(22-53)50-37(58)30(21-33(54)55)48-36(57)26(44)13-9-10-16-43/h6-8,11-12,23-24,26-32,34,53H,9-10,13-22,43-44H2,1-5H3,(H2,45,56)(H,46,61)(H,47,62)(H,48,57)(H,49,60)(H,50,58)(H,51,59)(H,54,55)/t26-,27-,28+,29-,30-,31-,32-,34-/m0/s1 |
InChI Key | HVUNRXRFMQDMBO-ICQHUDCBSA-N |
Isomeric SMILES | CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N)N1CC[C@H](C1=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)N |
BoilingPoint | 1342.8ºC at 760mmHg |
Melting Point | N/A |
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
3. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.